Medicare Advantage Can No Longer Cover These Items in 2026

Since a 2018 expansion of Medicare Advantage benefits, the Centers for Medicare & Medicaid Services has moved to impose new restrictions that will prevent plans from covering certain items that had previously been allowed. The change tightens benefit design for Medicare Advantage plans and may affect beneficiary out-of-pocket liabilities and plan competitiveness; investors should monitor CMS guidance for specific excluded items and assess potential enrollment or claims-cost implications for payors and managed-care insurers.

Analysis

Market structure: CMS restrictions on expanded Medicare Advantage (MA) benefits shrink addressable wallet for vendors of non-traditional benefits (home-based services, DME, remote monitoring), pressuring smaller suppliers and boutique MA vendors while favoring scale incumbents (UNH, HUM, ELV) that can internalize compliance costs. Expect 1–3% margin pressure on MA-focused revenue lines over 1–4 quarters for mid-cap suppliers; large diversified insurers will see revenue mix shifts but limited solvency impact.

Risk assessment: Tail risks include aggressive enforcement or retroactive clawbacks causing 5–10% surprise impairment for exposed vendors, or state-level litigation that reverses rule (low probability, high impact). Near-term (days–weeks) volatility will spike around CMS guidance releases; medium-term (3–12 months) earnings revisions will quantify revenue hits. Hidden dependencies: MA risk-adjustment mechanics and prior authorizations amplify P&L sensitivity; watch claims-runoff timing and provider contract repricings.

Trade implications: Direct winners are large, diversified payors and hospital systems able to capture displaced services; losers are small-cap DME/home-health and niche MA benefit vendors. Implement defensive hedges in insurers and short selective suppliers; favor hospital operators (HCA) and broader healthcare ETFs (XLV) for rotation out of niche vendors. Catalysts: CMS effective-date notices, insurer 10-Q/earnings, and state AG actions over next 30–90 days.

Contrarian angles: Consensus may over-penalize big insurers despite modest absolute revenue exposure—scale, risk-adjustment upside, and ability to redesign benefits could restore 1–2% EPS within 2–4 quarters. Historical parallel: 2015–2017 MA rule tweaks caused short-term downdrafts followed by re-pricing and product redesign—if CMS gives clear safe-harbors, recovery could be faster than current sentiment implies. Watch for unintended shift of spend back to fee-for-service providers, which would buoy hospital volumes.

Key Decisions for Investors

• Establish a 2–3% short position split between Humana (HUM) and UnitedHealth (UNH) over the next 30 days (size 1–1.5% each); target 6–12% downside within 3 months if CMS guidance materially reduces MA ancillary revenue, set stop-loss at +8%.
• Buy 90-day put spreads on HUM and UNH sized 1–2% notional each: 10–15% OTM put buy and 20–25% OTM sell to hedge regulatory tail risk and cap premium spend; roll or unwind on clear CMS implementation guidance (expected within 30–90 days).
• Enter a pair trade: overweight Elevance Health (ELV) by +2% and short HUM by -2% (1:1 dollar neutral) for 3–6 months, betting ELV’s diversified Medicaid/commercial mix is more resilient to MA benefit tightening; re-evaluate after next quarterly earnings.
• Reduce exposure to small-cap DME and home-health suppliers by 50% within 30 days and redeploy proceeds to HCA Healthcare (HCA) equal-weight position and +2% overweight to XLV (healthcare ETF) to capture reallocation of services back to hospitals and diversified healthcare names.
• Monitor 3 triggers in next 60 days before resizing positions: (1) CMS final rule effective date and implementing guidance, (2) insurer 10-Q/earnings language quantifying MA ancillary revenue impact >1% of premiums, (3) state litigation announcements — if two triggers confirm material hit, increase hedge sizes by +50%.